Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sisu Pharma Inc. has a patent portfolio currently active in the Biotechnology & Pharmaceuticals technology area. The company is managing 1 pending office action, which represents the total volume of its current prosecution activity. This matter is being handled by 1 distinct examiner and is located within 1 distinct art unit. Such a focused profile suggests a singular point of engagement with the patent office at this time.
The busiest examiner assigned to the portfolio is NOTTINGHAM, KYLE GREGORY, who is responsible for 1 pending office action. Since there is 1 pending action in the entire portfolio, this examiner holds the entirety of the company's active examination workload. Practitioners should note that the prosecution success for this portfolio currently rests on the interactions within this single art unit. The lack of multiple pending actions or examiners indicates a very specific phase of filing activity in this particular technology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18662751 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | NOTTINGHAM, KYLE GREGORY | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18662751 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | NOTTINGHAM, KYLE GREGORY | 1621 | §102DP | Non-Final OA | — | Pending | May 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSisu Pharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kyle Gregory Nottingham has the most, with 1 of Sisu Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
